Journal
JOURNAL OF ORGANIC CHEMISTRY
Volume 73, Issue 12, Pages 4496-4503Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jo8003953
Keywords
-
Categories
Ask authors/readers for more resources
The pentasaccharide sequence of the most active components of the antitumor drug PI-88, currently in phase II clinical trial, has been rapidly assembled in high overall yield and in only three steps starting from three monosaccharide building blocks. The procedure takes advantage of the first reported strategy of sequential one-pot glycosidations conducted exclusively under catalytic activation. In addition, the procedure relies only on shelf-stable and mild promoters such as Yb(OTf)(3) and Bi(OTf)(3).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available